CFO Kemula leaving CureVac

Pierre Kemula will depart Oct. 31 as CureVac N.V. (NASDAQ:CVAC) CFO. His departure, which comes after eight years at the company, coincides with a strategic shift from prophylactic vaccines to oncology and a headcount reduction of 30% of its employees by year-end.

Chemify Ltd., a University of Glasgow spinout aiming to use digitized chemistry techniques to design, discover and manufacture molecules, hired Kevin McGowan as chief business officer to help it scale its commercialization and operations and further expand into U.S. markets. McGowan was VP of biopharma growth at Blink Health Administration LLC...